Teva Pharmaceutical Industries LTD TEVA
We take great care to ensure that the data presented and summarized in this overview for TEVA PHARMACEUTICAL INDUSTRIES LTD is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TEVA
View all-
Black Rock Inc. New York, NY43MShares$684 Million0.02% of portfolio
-
Clal Insurance Enterprises Holdings LTD Tel Aviv, L339MShares$620 Million7.75% of portfolio
-
Ion Asset Management Ltd. George Town, Grand Cayman, E936.7MShares$583 Million48.01% of portfolio
-
Menora Mivtachim Holdings Ltd.28.4MShares$451 Million3.94% of portfolio
-
Exor Capital LLP London, X027.2MShares$432 Million17.5% of portfolio
-
Migdal Insurance & Financial Holdings Ltd.26MShares$414 Million8.23% of portfolio
-
Phoenix Holdings Ltd. Givatayim, L321.2MShares$337 Million6.52% of portfolio
-
State Street Corp Boston, MA19.4MShares$309 Million0.02% of portfolio
-
Rubric Capital Management LP New York, NY17MShares$270 Million6.19% of portfolio
-
Morgan Stanley New York, NY14.9MShares$237 Million0.02% of portfolio
Latest Institutional Activity in TEVA
Top Purchases
Top Sells
About TEVA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Insider Transactions at TEVA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 04
2025
|
Richard Daniell Exec. VP, European Commercial |
SELL
Open market or private sale
|
Direct |
12,936
-100.0%
|
$194,040
$15.56 P/Share
|
Mar 04
2025
|
Richard D Francis President and CEO |
SELL
Open market or private sale
|
Direct |
6,450
-2.56%
|
$96,750
$15.56 P/Share
|
Mar 04
2025
|
Eric A Hughes |
SELL
Open market or private sale
|
Direct |
5,174
-100.0%
|
$77,610
$15.56 P/Share
|
Mar 03
2025
|
Amir Weiss Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,179
+33.33%
|
-
|
Mar 03
2025
|
Mark Sabag |
BUY
Exercise of conversion of derivative security
|
Direct |
24,900
+9.77%
|
-
|
Mar 03
2025
|
Richard Daniell Exec. VP, European Commercial |
SELL
Open market or private sale
|
Direct |
49,314
-79.22%
|
$789,024
$16.19 P/Share
|
Mar 03
2025
|
Richard Daniell Exec. VP, European Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
62,250
+50.0%
|
-
|
Mar 03
2025
|
Richard D Francis President and CEO |
SELL
Open market or private sale
|
Direct |
24,892
-9.0%
|
$398,272
$16.19 P/Share
|
Mar 03
2025
|
Richard D Francis President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
67,231
+19.55%
|
-
|
Mar 03
2025
|
Eric A Hughes |
SELL
Open market or private sale
|
Direct |
19,726
-79.22%
|
$315,616
$16.19 P/Share
|
Mar 03
2025
|
Eric A Hughes |
BUY
Exercise of conversion of derivative security
|
Direct |
24,900
+50.0%
|
-
|
Mar 03
2025
|
Eliyahu Sharon Kalif EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
49,800
+20.12%
|
-
|
Feb 28
2025
|
Eliyahu Sharon Kalif EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
55,750
-27.37%
|
$892,000
$16.21 P/Share
|
Feb 18
2025
|
Richard D Francis President and CEO |
SELL
Open market or private sale
|
Direct |
75,506
-26.5%
|
$1,208,096
$16.95 P/Share
|
Feb 15
2025
|
Richard D Francis President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
161,655
+36.2%
|
-
|
Feb 12
2025
|
Mark Sabag |
SELL
Open market or private sale
|
Direct |
177,626
-46.43%
|
$2,842,016
$16.25 P/Share
|
Dec 20
2024
|
Roberto Mignone |
SELL
Open market or private sale
|
Indirect |
286,000
-29.15%
|
$6,292,000
$22.01 P/Share
|
Nov 20
2024
|
Christine Fox EVP, Head of U.S. Commercial |
SELL
Open market or private sale
|
Direct |
19,388
-30.54%
|
$310,208
$16.87 P/Share
|
Nov 20
2024
|
Christine Fox EVP, Head of U.S. Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
63,492
+50.0%
|
-
|
Sep 02
2024
|
Varda Shalev |
BUY
Exercise of conversion of derivative security
|
Direct |
12,872
+50.0%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 744K shares |
---|
Open market or private sale | 1.47M shares |
---|